Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.

Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, Yu Y, Lonard DM, Wang J, Wang SP, Edwards DG, Lavere PF, Shao J, Yi P, Jain A, Jung SY, Malovannaya A, Li S, Shao J, Roeder RG, Ellis MJ, Qin J, Fuqua SAW, O'Malley BW, Foulds CE.

Oncogene. 2018 Aug;37(33):4581-4598. doi: 10.1038/s41388-018-0284-2. Epub 2018 May 11.

2.

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.

Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S.

Breast Cancer Res. 2017 May 23;19(1):60. doi: 10.1186/s13058-017-0851-4.

3.

Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.

Li Z, Levine KM, Bahreini A, Wang P, Chu D, Park BH, Oesterreich S, Lee AV.

Endocrinology. 2018 Jan 1;159(1):285-296. doi: 10.1210/en.2017-00693.

4.

The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).

Najim O, Huizing M, Papadimitriou K, Trinh XB, Pauwels P, Goethals S, Zwaenepoel K, Peterson K, Weyler J, Altintas S, van Dam P, Tjalma W.

Cancer Treat Res Commun. 2019;19:100123. doi: 10.1016/j.ctarc.2019.100123. Epub 2019 Feb 21.

PMID:
30826563
5.

Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines.

Gelsomino L, Panza S, Giordano C, Barone I, Gu G, Spina E, Catalano S, Fuqua S, Andò S.

Cancer Lett. 2018 Aug 1;428:12-20. doi: 10.1016/j.canlet.2018.04.023. Epub 2018 Apr 24.

PMID:
29702197
6.

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.

Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS.

Int J Mol Sci. 2018 Feb 15;19(2). pii: E579. doi: 10.3390/ijms19020579.

7.

A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Herynk MH, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua SA.

Breast Cancer Res Treat. 2010 Jul;122(2):381-93. doi: 10.1007/s10549-009-0580-1. Epub 2009 Oct 20.

8.

Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.

Karmakar S, Foster EA, Smith CL.

Endocrinology. 2009 Apr;150(4):1588-96. doi: 10.1210/en.2008-1001. Epub 2008 Dec 18.

9.

Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

Zhao Y, Laws MJ, Guillen VS, Ziegler Y, Min J, Sharma A, Kim SH, Chu D, Park BH, Oesterreich S, Mao C, Shapiro DJ, Nettles KW, Katzenellenbogen JA, Katzenellenbogen BS.

Cancer Res. 2017 Oct 15;77(20):5602-5613. doi: 10.1158/0008-5472.CAN-17-1265. Epub 2017 Sep 13.

10.

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.

Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL.

Elife. 2016 Feb 2;5. pii: e12792. doi: 10.7554/eLife.12792.

11.

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I.

Cancer Res. 2013 Dec 1;73(23):6856-64. doi: 10.1158/0008-5472.CAN-13-1197. Epub 2013 Nov 11.

12.

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.

Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, Andò S, Fuqua SAW.

Breast Cancer Res Treat. 2016 Jun;157(2):253-265. doi: 10.1007/s10549-016-3829-5. Epub 2016 May 13. Erratum in: Breast Cancer Res Treat. 2017 Jun;163(3):639-640.

13.

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.

Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL.

Elife. 2018 Nov 29;7. pii: e37161. doi: 10.7554/eLife.37161.

14.

CUEDC1 is a primary target of ERα essential for the growth of breast cancer cells.

Lopes R, Korkmaz G, Revilla SA, van Vliet R, Nagel R, Custers L, Kim Y, van Breugel PC, Zwart W, Moumbeini B, Manber Z, Elkon R, Agami R.

Cancer Lett. 2018 Nov 1;436:87-95. doi: 10.1016/j.canlet.2018.08.018. Epub 2018 Aug 23.

15.

Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.

Chigira T, Nagatoishi S, Tsumoto K.

Biochem Biophys Res Commun. 2015 Aug 7;463(4):726-31. doi: 10.1016/j.bbrc.2015.06.002. Epub 2015 Jun 4.

PMID:
26049107
16.

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.

Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, Lai CF, Metodieva G, de Giorgio A, Williams RL, Santos DB, Gomez PJ, Lin ML, Metodiev MV, Stebbing J, Castellano L, Magnani L, Coombes RC, Buluwela L, Ali S.

Oncogene. 2017 Apr 20;36(16):2286-2296. doi: 10.1038/onc.2016.382. Epub 2016 Oct 17.

17.

Hakai acts as a coregulator of estrogen receptor alpha in breast cancer cells.

Gong EY, Park E, Lee K.

Cancer Sci. 2010 Sep;101(9):2019-25. doi: 10.1111/j.1349-7006.2010.01636.x.

18.

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.

Singh K, Munuganti RS, Leblanc E, Lin YL, Leung E, Lallous N, Butler M, Cherkasov A, Rennie PS.

Breast Cancer Res. 2015 Feb 25;17:27. doi: 10.1186/s13058-015-0529-8.

19.

Modulation of estrogen receptor alpha protein level and survival function by DBC-1.

Trauernicht AM, Kim SJ, Kim NH, Boyer TG.

Mol Endocrinol. 2007 Jul;21(7):1526-36. Epub 2007 May 1.

PMID:
17473282
20.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.

Endocr Relat Cancer. 2006 Dec;13(4):1121-33.

PMID:
17158758

Supplemental Content

Support Center